Merck & Co (NY:MRK)

139.82 -4.48 (-3.10%)

Delayed Quote Updated: 3:40 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

What To Expect From Merck’s (MRK) Q2 Earnings

July 27, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗

July 25, 2025

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Via Benzinga

Merck & Co. Inc. (NYSE:MRK): A Strong Value Investment with Undervalued Potential ↗

July 25, 2025

Merck & Co. (MRK) is a top value stock with strong fundamentals—undervalued P/E, high profitability, stable finances, and steady growth, making it a smart pick for value investors.

Via Chartmill

P/E Ratio Insights for Merck & Co ↗

July 24, 2025

Via Benzinga

Merck Commits To Veeva’s Vault CRM, Draws Wall Street Cheer: Retail’s Not Enthusiastic ↗

July 21, 2025

Via Stocktwits

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided ↗

July 21, 2025

Via Stocktwits

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

July 28, 2025

If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering yields of up to 3.9%.

Via The Motley Fool

Topics Lawsuit

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact ↗

July 28, 2025

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Via Benzinga

Merck & Co's Earnings Outlook ↗

July 28, 2025

Via Benzinga

How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings ↗

July 28, 2025

Merck offers a quarterly dividend amount of 81 cents per share. To receive $500 monthly, here's what you do.

Via Benzinga

3 Surprisingly Underrated Stocks to Buy Right Now ↗

July 28, 2025

These big pharma stocks arguably aren't receiving the respect they deserve.

Via The Motley Fool

Topics Intellectual Property

Merck & Co Unusual Options Activity For July 15 ↗

July 15, 2025

Via Benzinga

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic ↗

July 15, 2025

Via Stocktwits

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗

July 23, 2025

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.

Via Investor's Business Daily

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock ↗

July 22, 2025

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Via Investor's Business Daily

Merck Announces Fourth-Quarter 2025 Dividend

July 22, 2025

From Merck & Co., Inc.

Via Business Wire

MERCK & CO. INC. (NYSE:MRK) – A Quality Stock with Strong Fundamentals ↗

July 22, 2025

MERCK & CO. INC. (NYSE:MRK) is a high-quality stock with strong profitability, efficient capital use, and a reliable dividend, making it a solid pick for long-term investors.

Via Chartmill

Does This Move Make Merck Stock a Buy? ↗

July 20, 2025

Via The Motley Fool

Topics Intellectual Property

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? ↗

July 20, 2025

Via The Motley Fool

Topics Economy Intellectual Property

Want Decades of Passive Income? Buy This ETF and Hold It Forever ↗

July 19, 2025

Via The Motley Fool

Topics ETFs Regulatory Compliance Stocks

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 19, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗

July 19, 2025

Via The Motley Fool

Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business ↗

July 17, 2025

Via The Motley Fool

Topics Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

July 16, 2025

Via Benzinga

1 Dow Jones Stock to Target This Week and 2 to Avoid

July 16, 2025

While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising costs, or disruptive new competitors.

Via StockStory

Topics Stocks

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults ↗

July 15, 2025

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

Via Benzinga

This House of Representative Just Bought Up To $30K In 3M Stock ↗

July 15, 2025

Via Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.